Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.
Attacking the Origin of IgAN: ORIGIN3 and Atacicept
ORIGIN-3: The Visual Abstract
ORIGIN-3: El Resumen Visual
ORIGIN-3 ha llegado a NephJC con atacicept en NIgA.
Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras!
Revisa el resumen visual realizado por Clemens Weber
ASIs Advance: NephJC Shorts on BaxHTN
NephJC Shorts: The end of the Fluid Wars?
CONFIDENCE manifests: finerenone & empagliflozin – CKD power couple that’s redefining ‘renal romance’
Check out CONFIDENCE recap
A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance
Does Lorundrostat Effectively Lower Blood Pressure in Uncontrolled Hypertension?
Stunning visual abstract summarizing NEJM study, by Priti Meena
Is a lower BP the road to better outcomes in diabetes?
How low is too low for blood pressure? Will BPROAD get to the bottom of this issue?
Microvascular inflammation of kidney allografts
Microvascular inflammation from the perspective of a real unicorn: donor-specific antibodies with negative antibody mediated rejection 🦄
Kidney Allografts-Play With Fire, Get Burned
REGENCY: A B-Cell Super Destroyer in Lupus
BPROAD: Sprinting down the BP Road in Diabetes
Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?
Trial by Combat: Do Amino Acids provide PROTECTION to the Kidneys?
FLOW - El Resumen Visual
¡La Marea de Semaglutida llegó a la Enfermedad Renal Crónica!
Del monstruo de Gila al estudio FLOW.
Para ello, veamos el hermoso resumen visual realizado por la pasante de NephEdC, Anjana Gopal, traducido por Milagros Flores.
FLOW- the Visual Abstract
‘FLOW’ing with the Semaglu’TIDE’!
Check the beautiful visual abstract made by NephEdC intern Anjana Gopal, with an appearance of the Gila monster as well.
